Protara Therapeutics Statistics
Want to see TARA full AI Analyst Report?
Protara Therapeutics (TARA) Stock Statistics & Valuation Metrics
Total Valuation
Protara Therapeutics has a market cap or net worth of $149.62M. The enterprise value is $93.30M.
- Market Cap
- $149.62M
- Enterprise Value
- $93.30M
Share Statistics
Protara Therapeutics has 61,570,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 61,570,350
- Owned by Insiders
- 2.84%
- Owned by Institutions
- 19.38%
Financial Efficiency
Protara Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -32.31%.
- Return on Equity (ROE)
- -0.29
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -32.31%
- Return on Capital Employed (ROCE)
- -0.33
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.25M
- Employee Count
- 46
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Protara Therapeutics is -1.74. Protara Therapeutics’s PEG ratio is -1.14.
- PE Ratio
- -1.74
- PS Ratio
- 0.00
- PB Ratio
- 1.08
- Price to FCF
- -1.96
- Price to Operating Cash Flow
- -2.12
- PEG Ratio
- -1.14
Income Statement
In the last 12 months, Protara Therapeutics had revenue of 0 and earned -57.44M in profits. Earnings per share was -1.34.
- Revenue
- 0
- Gross Profit
- -362.00K
- Operating Income
- -64.55M
- Pretax Income
- -57.44M
- Net Income
- -57.44M
- EBITDA
- -57.08M
- Earnings Per Share (EPS)
- -1.34
Cash Flow
In the last 12 months, operating cash flow was -72.12M and capital expenditures -1.08M, giving a free cash flow of -73.20M billion.
- Operating Cash Flow
- -72.12M
- Free Cash Flow
- -73.20M
- Free Cash Flow per Share
- -1.16
Dividends & Yields
Protara Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -50.78%
- Earnings Yield
- -51.16%
Stock Price Statistics
- Beta
- 0.87
- 52-Week Price Change
- -46.36%
- 50-Day Moving Average
- 3.03
- 200-Day Moving Average
- 4.45
- Relative Strength Index (RSI)
- 44.18
- Average Volume (3m)
- 996.06K
Important Dates
Protara Therapeutics upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Protara Therapeutics as a current ratio of 14.58, with Debt / Equity ratio of 1.71%
- Current Ratio
- 14.58
- Quick Ratio
- 14.58
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.81
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Protara Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Protara Therapeutics EV to EBITDA ratio is -1.52, with an EV/FCF ratio of -1.66.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.52
- EV to Free Cash Flow
- -1.66
- EV to Operating Cash Flow
- -1.68
Balance Sheet
Protara Therapeutics has $127.05M in cash and marketable securities with $2.44M in debt, giving a net cash position of $124.61M billion.
- Cash & Marketable Securities
- $127.05M
- Total Debt
- $2.44M
- Net Cash
- $124.61M
- Net Cash Per Share
- $2.02
- Tangible Book Value Per Share
- $2.24
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Protara Therapeutics is $26.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $26.00
- Price Target Upside
- 969.96% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 4.03%
Scores
- Smart Score
- 6
- AI Score
- 41
